Dr Elin Haf Davies is the CEO & Founder of Aparito.
Dr Elin Haf Davies founded Aparito in 2014 on the back of 21 years of clinical (as Senior Clinical Research Nurse and Trial Administrator, Great Ormond Street Children’s Hospital, London), research (PhD, University College London, UK) and regulatory experience (as Scientific Assessor at both the Medicines Health Regulatory Authority (MHRA) and the European Medicine Agency (EMA)).
At the EMA Elin Haf was part of the core team responsible for implementing the E.U. Paediatric Regulation which came into force in January 2007.
Elin continues to be involved in the research and development of new and emerging drug treatments for rare diseases in children. Her PhD – focusing on developing new outcome measures for gait and ataxia in children with neuro-Lysosomal Storage Disorders resulted in many peer-reviewed journals. Since 2013, Elin Haf has been an Associate Fellow at the Centre for the Advancement of Sustainable Medical Innovation (CASMI) and an Academic Fellow at Bangor University since 2014 dedicated to the cost evaluation of orphan drugs.
Her considerable career in clinical, academic and regulatory fields, combined with extensive dialogue and collaboration with patient groups, means that she brings innovation and designs as a solution to all stakeholder groups. Elin’s passion has always been to inspire children, especially those with chronic illnesses, to be empowered and engaged in their own lives.
Aparito was founded as a tech solution to contribute to patient empowerment in the drug development pathway and completely transform the way clinical studies are conducted and novel eCOA are developed.
In addition to her work at Aparito, Elin is the Chair of Metabolic Support UK, the leading patient organisation for Inherited Metabolic Disorders supporting thousands of patients worldwide.